We didn't build a product and find research to support it.
We started with the research.
Four decades of published phototherapy science. Three of the most cited vitamin D researchers in the world. One 12-week cohort study with results we'll show you in full — including the limitations.
THE ORIGIN OF THE SCIENCE
Before there was an Enyrgy platform, there was a clinical study.
In 2020, co-founders Scott Hansbury and David Letourneau began speaking with physicians from Louisiana State University and Baylor University on a study using UVB light to boost immune response in critically ill COVID-19 patients. The results showed a 60% reduction in mortality.
The research on vitamin D, UVB synthesis, and immune function that came out of those conversations was the scientific foundation for everything we built after.
We assembled the advisory board before we designed the product. The protocol before the hardware. The peer-reviewed methodology before the marketing copy.
Our protocol was designed by Dr. Samantha Kimball, Dr. Bruce Hollis, and Dr. William Grant — three of the most cited vitamin D researchers in the world. Their combined published work spans 500+ peer-reviewed papers and 70,000+ citations.
WHAT FOUR DECADES OF SCIENCE SAYS
The Enyrgy platform is fairly new.
The underlying science is not.
The following peer-reviewed research forms the foundation of how we understand UVB synthesis, UVA-triggered pathways, and the difference between natural synthesis and oral supplementation. These studies examine the normal structure and function of the healthy human body. They are not intended to imply disease treatment.
UVB-Triggered Vitamin D Synthesis
Holick, M.F. (2007). Vitamin D deficiency. New England Journal of Medicine, 357(3), 266–281.
Webb, A.R., et al. (2017). Influence of season and latitude on the cutaneous synthesis of vitamin D3. Journal of Clinical Endocrinology and Metabolism.
Chel, V., et al. (2008). Efficacy of different doses and time intervals of oral vitamin D supplementation. Osteoporosis International.
UVA-Induced Nitric Oxide Release
Liu, D., et al. (2014). UVA irradiation of human skin vasodilates arterial vasculature and lowers blood pressure. Journal of Investigative Dermatology, 134(7), 1839–1846.
Feelisch, M., et al. (2010). Is sunlight good for our heart? European Heart Journal, 31(9), 1041–1045.
UVA-Triggered Serotonin Production
Gambichler, T., et al. (2002). Plasma levels of opioid peptides after repeated exposure to ultraviolet radiation. British Journal of Dermatology, 147(6), 1207–1211.
Kaur, M., et al. (2019). Role of serotonin in seasonal affective disorder. European Review for Medical and Pharmacological Sciences.
Natural Synthesis vs. Oral Supplementation
Heaney, R.P., et al. (2011). Nutrients, 6(10), 4472–4475.
Luxwolda, M.F., et al. (2012). Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/l. British Journal of Nutrition, 108(9), 1557–1561.
THIRD-PARTY SPECTRUM VERIFICATION
Our spectrum output is not a manufacturer claim.
An independent laboratory has conducted spectral analysis of the Enyrgy device output and confirmed: 90 to 95% UVB (280 to 315nm) and 5 to 10% UVA. That is the Triple-Pathway Advantage ratio we reference throughout the platform.
The verification documentation is available upon request.
90–95%
UVB output
5–10%
UVA output
This is a Paragraph Font
12-WEEK OBSERVATIONAL STUDY RESULTS
Real participants. Real labs.
We'll show you every number.
We ran a 12-week internal observational cohort study to validate the mechanism in real users under controlled conditions.
STUDY DESIGN
N=5 participants · Skin types II through IV · Healthy adults without contraindications · No control group (observational design) · Average 5.1 sessions per week over 12 weeks
+111%
Average increase from baseline
39.96→84.20
ng/mL average baseline to optimal
100%
Participants reaching optimal range
0
Adverse events
INDIVIDUAL RESULTS
Participant 1 — Male, Skin Type II
38.4 → 86.0 ng/mL · +124% · 82 sessions
Participant 2 — Male, Skin Type III
34.0 → 88.4 ng/mL · +160% · 43 sessions
Participant 3 — Male, Skin Type III
37.0 → 78.0 ng/mL · +111% · 51 sessions
Participant 4 — Male, Skin Type IV
47.0 → 88.7 ng/mL · +89% · 85 sessions
Participant 5 — Female, Skin Type III
43.4 → 79.9 ng/mL · +84% · 47 sessions
STUDY LIMITATIONS
Small sample size (N=5). No control group — this is observational data, not a randomized controlled trial. All participants were highly compliant in-office sessions. All participants were healthy adults without contraindications.
What we're pursuing next: A larger-scale independent peer-reviewed trial. Protocol in development, targeting Q3 2026. Full study protocol and raw data available on request.
THE HONEST CASE
The research behind Enyrgy is strong. Four decades of published science, three of the most credible researchers in the field, and cohort data showing 100% of participants reaching optimal levels with zero adverse events.
We could present that without context. We chose not to.
The cohort study is small. The sample is not diverse enough to draw population-level conclusions. We are not a medical device and we do not treat, diagnose, or prevent any medical condition.
What we are is a precision phototherapy platform grounded in peer-reviewed science, validated by independent spectral testing, and designed by researchers who have spent their careers studying exactly this mechanism.
That is the honest case. We're comfortable with it.
Quick Links
Our Story
The Platform
The Science
FAQ
Shop
Contact
Privacy Policy
Terms of Service
Refund, Return and Warranty Policy
Shipping Policy
Must be 18 years or older to be eligible for treatment. Enyrgy is not a medical device, and makes no medical claims, implied or otherwise stated, for the use of this device other than the fact it will emit UV light within the ranges and levels per the product specification. Statements regarding the Enyrgy device have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease or health condition.
© 2026, Enyrgy Inc.